EXPERIENCE WITH TRILOSTANE IN THE TREATMENT OF CUSHING'S SYNDROME
- 1 June 1983
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 18 (6) , 533-540
- https://doi.org/10.1111/j.1365-2265.1983.tb00590.x
Abstract
Five patients with pituitary dependent Cushing''s syndrome and 2 with adrenal carcinoma were treated with increasing doses of trilostane (up to 1440 mg daily). There was no consistent fall in serum cortisol levels. In addition there was no rise in the levels of precursors immediately preceding the proposed site of action of trilostane. Apparently, trilostane does not effectively block the enzyme 3.beta.-hydroxysteroid dehydrogenase .DELTA.4,.DELTA.5 isomerase in patients with Cushing''s syndrome and it should no longer be recommended for their treatment.This publication has 8 references indexed in Scilit:
- TRILOSTANE AS CAUSE OF ADDISONIAN CRISISThe Lancet, 1981
- Inhibition of Ovarian, Placental, and Adrenal Steroidogenesis in the Rhesus Monkey by TrilostaneFertility and Sterility, 1979
- Treatment of Cushing's Syndrome with Trilostane (WIN 24,540), an Inhibitor of Adrenal Steroid Biosynthesis*Journal of Clinical Endocrinology & Metabolism, 1978
- Trilostane, an orally active inhibitor of steroid biosynthesisSteroids, 1978
- CUSHING'S SYNDROME, NODULAR ADRENAL HYPERPLASIA AND VIRILIZING CARCINOMAClinical Endocrinology, 1978
- Plasma 16 β-Hydroxydehydroepiandrosterone in Normal and Pathological Conditions in Man1Journal of Clinical Endocrinology & Metabolism, 1976
- A simple method for the assay of eight steroids in small volumes of plasmaSteroids, 1976
- Steroidal heterocycles. XIII. 4.alpha.,5-Epoxy-5.alpha.-androst-2-eno[2,3-d]isoxazoles and related compoundsJournal of Medicinal Chemistry, 1970